“The veterinary arthritis treatment using TISTEM’s’incapacitated stem cells’ will be approved as an item in March next year as soon as it has completed clinical trials.”
At the ‘2020 Korea Bio-investment Conference (KBIC)’ held on the 29th, Kim Young-sil, the CEO of Tistem, introduced the membraneless stem cell developed by the company.
Membrane stem cells are obtained by removing the cell membrane of human-derived fat stem cells and separating and purifying only anti-inflammatory and regenerative factors. It has the advantage of being inexpensive and easy to use by supplementing the shortcomings of existing stem cells that can only be treated by the patient himself.
He said, “The membraneless stem cells that can be carried at room temperature are convenient to use and distribute and can be mass-produced,” he said. “With nanofilter purification technology, only active ingredients that have anti-inflammatory and regenerating effects are purified and freeze-dried to make distribution and use easier. I made it.”
CEO Kim said, “Based on the anti-inflammatory and regenerative action, it can be applied to various products and pharmaceuticals to create industrial value.” Compared to the representative steroid drug dexamethasone, the inhibitory effect of inflammatory cytokines (TNF-∝) was similar. It explains that the effect of producing regenerative cytokines (TGF-β) was increased.
He said, “Tistem holds the original technology and patents in the entire process, from supply and demand of adipose tissue, which is a raw material, to manufacturing of membraneless stem cells, and production of finished products.” We research and develop and sell.”
Tistem is also developing a treatment for arthritis for animals and a treatment for skin diseases for animals. CEO Kim said, “We expect to receive product approval as early as next March, as an arthritis treatment for animals with no membrane stem cells.”
Regarding the listing plan, he said, “We are aiming to be listed on special technology cases in 2022. We will become a company that achieves profits on the premise of approval for veterinary drugs and entry into clinical trials for human drugs.”
Reporter Kim Ye-na [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution